NO20083191L - Farmasoytisk sammensetning for behandling av hemoragisk sjokk og dens etterfolgende symptomer - Google Patents

Farmasoytisk sammensetning for behandling av hemoragisk sjokk og dens etterfolgende symptomer

Info

Publication number
NO20083191L
NO20083191L NO20083191A NO20083191A NO20083191L NO 20083191 L NO20083191 L NO 20083191L NO 20083191 A NO20083191 A NO 20083191A NO 20083191 A NO20083191 A NO 20083191A NO 20083191 L NO20083191 L NO 20083191L
Authority
NO
Norway
Prior art keywords
pro
peptide
arg
gly
pharmaceutical composition
Prior art date
Application number
NO20083191A
Other languages
English (en)
Norwegian (no)
Inventor
Peter Petzelbauer
Rainer Henning
Original Assignee
Fibrex Medical Res & Dev Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrex Medical Res & Dev Gmbh filed Critical Fibrex Medical Res & Dev Gmbh
Publication of NO20083191L publication Critical patent/NO20083191L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20083191A 2005-12-23 2008-07-17 Farmasoytisk sammensetning for behandling av hemoragisk sjokk og dens etterfolgende symptomer NO20083191L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0206705A AT502987A1 (de) 2005-12-23 2005-12-23 Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
PCT/AT2006/000465 WO2007070899A2 (fr) 2005-12-23 2006-11-10 Composition pharmaceutique destinee au traitement d'un choc hemorragique et de ses consequences

Publications (1)

Publication Number Publication Date
NO20083191L true NO20083191L (no) 2008-09-16

Family

ID=37846035

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083191A NO20083191L (no) 2005-12-23 2008-07-17 Farmasoytisk sammensetning for behandling av hemoragisk sjokk og dens etterfolgende symptomer

Country Status (14)

Country Link
US (1) US7897574B2 (fr)
EP (2) EP2110136A3 (fr)
JP (1) JP2009520696A (fr)
KR (1) KR20080108221A (fr)
CN (1) CN101365477A (fr)
AT (2) AT502987A1 (fr)
AU (1) AU2006326890A1 (fr)
CA (1) CA2634026A1 (fr)
DE (1) DE502006004619D1 (fr)
ES (1) ES2331970T3 (fr)
IL (1) IL192349A0 (fr)
NO (1) NO20083191L (fr)
RU (1) RU2008130413A (fr)
WO (1) WO2007070899A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799758B2 (en) * 2006-02-23 2010-09-21 Ikaria Development Subsidiary Two, LLC Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
EP2193370A2 (fr) * 2007-09-24 2010-06-09 Fibrex Medical Research & Development GmbH Procédés d'analyse de composés à activité antiinflammatoire
WO2012078736A2 (fr) * 2010-12-09 2012-06-14 The Brigham And Women's Hospital, Inc. Fibrinogène et lésions rénales
US20170112941A1 (en) * 2015-10-13 2017-04-27 Symic Ip, Llc Ve-cadherin binding bioconjugate
JP7506364B2 (ja) * 2019-10-24 2024-06-26 国立大学法人東海国立大学機構 慢性肺疾患／急性呼吸窮迫症候群の治療薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997844A (en) 1991-02-08 1999-12-07 Diatide, Inc. Technetium-99m labeled peptides for imaging
CN1518558B (zh) 2000-12-12 2010-06-16 菲布雷克斯医疗研究及开发有限责任公司 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途
US20080311103A1 (en) * 2004-03-08 2008-12-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Anti-Inflammatory Peptides and Methods of Use Thereof
AT414097B (de) 2004-06-25 2006-09-15 Petzelbauer Peter Dr Pharmazeutische zubereitung zur behandlung von schock
PT1691827E (pt) 2004-06-25 2009-11-23 Fibrex Medical Res & Dev Gmbh Utilização de péptidos derivados da cadeia b beta de fibrinogénio humano para o tratamento do choque

Also Published As

Publication number Publication date
US7897574B2 (en) 2011-03-01
ES2331970T3 (es) 2010-01-21
EP1962887A2 (fr) 2008-09-03
IL192349A0 (en) 2008-12-29
WO2007070899A2 (fr) 2007-06-28
WO2007070899A3 (fr) 2007-10-04
AT502987A1 (de) 2007-07-15
CA2634026A1 (fr) 2007-06-28
AU2006326890A1 (en) 2007-06-28
KR20080108221A (ko) 2008-12-12
RU2008130413A (ru) 2010-01-27
EP2110136A3 (fr) 2010-01-27
US20090005310A1 (en) 2009-01-01
EP2110136A2 (fr) 2009-10-21
CN101365477A (zh) 2009-02-11
EP1962887B1 (fr) 2009-08-19
ATE440282T1 (de) 2009-09-15
DE502006004619D1 (de) 2009-10-01
JP2009520696A (ja) 2009-05-28

Similar Documents

Publication Publication Date Title
Li et al. Stress induction of GRP78/BiP and its role in cancer
Simão et al. Resveratrol preconditioning modulates inflammatory response in the rat hippocampus following global cerebral ischemia
Kaur et al. Therapeutic evaluation of rutin in two-kidney one-clip model of renovascular hypertension in rat
Li et al. Atorvastatin decreases C‐reactive protein‐induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor‐κB pathway
SE9800836D0 (sv) New Compounds
NO20044459L (no) Anvendelse av IL-18-inhibitorer for behandlingen og/eller forebyggingen av perifere vaskulaere sykdomrner
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
IL194843A0 (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
IL192349A0 (en) Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms
Wang et al. SIRT1 as a novel potential treatment target for vascular aging and age-related vascular diseases
DK1874341T3 (da) Erythrocytter, der indeholder arginin deiminase
ATE435657T1 (de) Therapeutische zubereitung von hochreinem fviia und verfahren zu dessen gewinnung
Lv et al. Aucubin and its hydrolytic derivative attenuate activation of hepatic stellate cells via modulation of TGF-β stimulation
Keck et al. Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis
Knipp et al. Increased MMP-9 expression and activity by aortic smooth muscle cells after nitric oxide synthase inhibition is associated with increased nuclear factor-κB and activator protein-1 activity
DE502006006466D1 (de) Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen
Qiu et al. The therapeutic efficacy of Ulinastatin for rats with smoking inhalation injury
Wittig et al. Endothelial-dependent S-Sulfhydration of tissue factor pathway inhibitor regulates blood coagulation
DK1233787T3 (da) Produkt, der inhiberer signaltransduktion fra heterotrimere G-proteiner, kombineret med et andet cancerbekæmpende middel til terapeutisk anvendelse i cancerbehandlingen
NO20080781L (no) GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer
Bontor et al. Sulodexide protects endothelial cells against 4-hydroxynonenal-induced oxidative stress and glutathione-dependent redox imbalance by modulation of sestrin2/nuclear factor erythroid 2-related factor 2 pathway.
ATE289319T1 (de) Dipeptidische hemmstoffe für den gerinnungsfaktor xa
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
Cao et al. Inhibitory effects of baicalin on IL-1β-induced MMP-1/TIMP-1 and its stimulated effect on Collagen-I production in human periodontal ligament cells

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application